newsfilter
← Latest News
Business Wire·

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

Kezar Life Sciences, Inc. (NASDAQ:KZR, the Company)), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced regulatory